← Back to Analyst Consensus 
CTKB Buy
Cytek Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 13, 2026 | Stephens & Co. | maintain | Overweight → Overweight | — | 54% |
| May 12, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Jan 8, 2026 | TD Cowen | maintain | Buy → Buy | $5 | 54% |
| Nov 11, 2025 | Piper Sandler | maintain | Overweight → Overweight | $7.5 | 54% |
| May 28, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $7 | 54% |
| May 12, 2025 | Goldman Sachs | maintain | Sell → Sell | $3 | 54% |
| Mar 19, 2025 | Stephens & Co. | reiterate | Overweight → Overweight | $6 | 54% |
| Mar 4, 2025 | Piper Sandler | maintain | Overweight → Overweight | $8 | 54% |
| Nov 11, 2024 | Piper Sandler | maintain | Overweight → Overweight | $8.5 | 54% |
| Aug 13, 2024 | Piper Sandler | maintain | Overweight → Overweight | $8 | 54% |
| May 13, 2024 | Piper Sandler | maintain | Overweight → Overweight | $8.5 | 54% |
| Mar 6, 2024 | Piper Sandler | maintain | Overweight → Overweight | $10 | 54% |
| Feb 29, 2024 | Goldman Sachs | maintain | Buy → Buy | $10 | 54% |
| Dec 14, 2023 | Stephens & Co. | initiate | — → Overweight | $9 | 54% |
| Nov 9, 2023 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $7 | 54% |
| Oct 24, 2023 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $8 | 54% |
| Oct 16, 2023 | Piper Sandler | maintain | Overweight → Overweight | $10 | 54% |
| Jul 19, 2023 | Raymond James | initiate | — → Market Perform | $0 | 54% |
| May 11, 2023 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $13 | 54% |
| May 10, 2023 | Goldman Sachs | maintain | — → Buy | $12 | 54% |
| Mar 7, 2023 | Piper Sandler | maintain | — → Overweight | $15 | 54% |
| Mar 2, 2023 | Morgan Stanley | maintain | — → Equal-Weight | $14 | 54% |
| Mar 2, 2023 | Goldman Sachs | maintain | — → Buy | $14 | 54% |
| Aug 18, 2022 | Piper Sandler | maintain | — → Overweight | $16 | 54% |
| Aug 12, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $15 | 54% |
| Aug 11, 2022 | Goldman Sachs | maintain | — → Buy | $17 | 54% |
| Jul 14, 2022 | Goldman Sachs | maintain | — → Buy | $15 | 54% |
| May 16, 2022 | Piper Sandler | maintain | — → Overweight | $12 | 54% |
| May 13, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $11 | 54% |
| May 12, 2022 | Goldman Sachs | maintain | — → Buy | $12 | 54% |
| Apr 13, 2022 | Goldman Sachs | maintain | — → Buy | $14 | 54% |
| Feb 15, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $18 | 54% |
| Aug 17, 2021 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Aug 17, 2021 | Morgan Stanley | initiate | — → Equal-Weight | $26 | 54% |
| Aug 17, 2021 | Goldman Sachs | initiate | — → Buy | $28 | 54% |
| Aug 17, 2021 | Piper Sandler | initiate | — → Overweight | $28 | 54% |
Price Target Trend
Apr 28, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days